IL319599A - טיפול קומבינציה - Google Patents

טיפול קומבינציה

Info

Publication number
IL319599A
IL319599A IL319599A IL31959925A IL319599A IL 319599 A IL319599 A IL 319599A IL 319599 A IL319599 A IL 319599A IL 31959925 A IL31959925 A IL 31959925A IL 319599 A IL319599 A IL 319599A
Authority
IL
Israel
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
IL319599A
Other languages
English (en)
Inventor
Jolanta Skarbaliene
Per-Olof Eriksson
Original Assignee
Zealand Pharma As
Jolanta Skarbaliene
Eriksson Per Olof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Jolanta Skarbaliene, Eriksson Per Olof filed Critical Zealand Pharma As
Publication of IL319599A publication Critical patent/IL319599A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL319599A 2022-09-19 2023-09-19 טיפול קומבינציה IL319599A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22196432 2022-09-19
EP22199281 2022-09-30
PCT/EP2023/075821 WO2024061919A1 (en) 2022-09-19 2023-09-19 Combination therapy

Publications (1)

Publication Number Publication Date
IL319599A true IL319599A (he) 2025-05-01

Family

ID=88098166

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319599A IL319599A (he) 2022-09-19 2023-09-19 טיפול קומבינציה

Country Status (10)

Country Link
EP (1) EP4590326A1 (he)
JP (1) JP2025530325A (he)
KR (1) KR20250069663A (he)
CN (1) CN119923269A (he)
AU (1) AU2023346836A1 (he)
CA (1) CA3266672A1 (he)
CL (1) CL2025000769A1 (he)
IL (1) IL319599A (he)
MX (1) MX2025003208A (he)
WO (1) WO2024061919A1 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025262301A1 (en) * 2024-06-20 2025-12-26 Zealand Pharma A/S Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake
WO2026052861A1 (en) * 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052859A1 (en) * 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
CN119161446B (zh) * 2024-11-22 2025-02-14 杭州诺泰诺和生物医药科技有限公司 胰淀素类似物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK88793A3 (en) 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
WO2012168430A2 (en) 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
KR20150006052A (ko) 2012-05-03 2015-01-15 질랜드 파마 에이/에스 글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CA3138715A1 (en) * 2019-06-14 2020-12-17 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
JP7751641B2 (ja) * 2020-12-16 2025-10-08 ジーランド ファーマ エー／エス Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物

Also Published As

Publication number Publication date
JP2025530325A (ja) 2025-09-11
CA3266672A1 (en) 2024-03-28
WO2024061919A1 (en) 2024-03-28
EP4590326A1 (en) 2025-07-30
CN119923269A (zh) 2025-05-02
MX2025003208A (es) 2025-04-02
AU2023346836A1 (en) 2025-03-20
CL2025000769A1 (es) 2025-07-11
KR20250069663A (ko) 2025-05-19

Similar Documents

Publication Publication Date Title
CA221425S (en) Therapy eye-mask
IL319599A (he) טיפול קומבינציה
IL304223A (he) טיפול משולב
GB202004189D0 (en) Combination therapy
IL318268A (he) טיפול משולב
GB202002639D0 (en) Therapy
GB202111288D0 (en) Combination therapy
GB202104037D0 (en) Combination therapy
IL325619A (he) טיפול משולב
GB202318311D0 (en) Combination therapy
GB202317996D0 (en) Combination therapy
GB202316168D0 (en) Combination therapy
GB202315149D0 (en) Combination therapy
GB202314243D0 (en) Combination therapy
GB202314157D0 (en) Combination therapy
GB202306663D0 (en) Combination therapy
GB202218974D0 (en) Combination therapy
GB202207792D0 (en) Combination therapy
GB202205317D0 (en) Combination therapy
GB202201346D0 (en) Combination therapy
GB202315877D0 (en) Therapy
GB202306826D0 (en) Therapy
GB202306835D0 (en) Therapy
GB202306833D0 (en) Therapy
GB202303026D0 (en) Therapy